Vasee Moorthy - Concepedia

Author

Vasee Moorthy

Also Known As

Olivier Lapujade, V Moorthy, V. Moorthy, V.S. Moorthy, VS Moorthy, Vasee Moorthy, Vasee S Moorthy, Vasee S. Moorthy, Vasee Sathiyamoorthy, Vaseeharan Sathiyamoorthy

114

Publications

Citations

H-Index

Concepts

All Affiliations

World Health Organization University of Oxford John Radcliffe Hospital London School of Hygiene & Tropical Medicine University Medical Center Hamburg-Eppendorf

About

Vasee Moorthy is an author at World Health Organization specializing in medicine, vaccination, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	24	2.3K
2	Public Health	4	4	324
3	Education	1	1	149
4	Health Sciences	1	1	28
5	Allergy	1	1	31

Vasee Moorthy

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Samuel McConkey, William H. H. Reece, Vasee Moorthy, Nature Medicine VaccinationVaccine DevelopmentImmunologyPlasmid Dna VaccinesTherapeutic Vaccine	2003	557
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser, New England Journal of Medicine	2015	404
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial Angela Huttner, Julie-Anne Dayer, Sabine Yerly, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyPreventive MedicineImmunology	2015	276
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial Milagritos D. Tapia, Samba O. Sow, Kirsten E. Lyke, The Lancet Infectious Diseases	2015	213
WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23–24 March 2015 Kayvon Modjarrad, Birgitte Giersing, David C. Kaslow, Vaccine Respiratory Virus ImmunityRespiratory ComplicationsVaccine HesitancyRsv BiologyVaccine Surveillance	2015	202
A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults Vasee Moorthy, Egeruan B. Imoukhuede, Paul Milligan, PLoS Medicine	2004	179
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study Olga De Santis, R Audran, Emilie Pothin, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing	2015	151
Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results Vasee Moorthy, Ghassan Karam, Kirsten Vannice, PLoS Medicine Evidence-based MedicineEducationPrompt ReportingResearch EthicsHealth Communication	2015	149
Ebola Vaccine — An Urgent International Priority Rupa Kanapathipillai, Ana María Henao-Restrepo, Patricia Fast, New England Journal of Medicine World Health OrganizationImmunologyDisease OutbreakEmerging Infectious DiseaseInfection Control	2014	126
Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria Sheila M. Keating, Philip Bejon, Tamara Berthoud, The Journal of Immunology VaccinationAutoimmune DiseaseVaccine DevelopmentLaboratory ImmunologyVaccine Research	2005	125

Page 1